You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Article metrics

Article menu

This article has a correction. Please see:

Case report
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

 

Online download statistics by month:

Online download statistics by month: April 2022 to January 2026

AbstractFullPdf
Apr 2022861888327
May 2022428460212
Jun 2022659672120
Jul 202221321856
Aug 202224824865
Sep 202220721155
Oct 202223825075
Nov 202220220946
Dec 202217217454
Jan 202317117151
Feb 202324925097
Mar 2023276276136
Apr 2023207207112
May 202324124372
Jun 202318618950
Jul 202311311450
Aug 2023939450
Sep 202311511747
Oct 202311411477
Nov 202310610151
Dec 202311812063
Jan 202412712862
Feb 202412612586
Mar 2024172173125
Apr 202414915171
May 202410210459
Jun 2024969664
Jul 202412412871
Aug 2024919386
Sep 202410510580
Oct 202412412881
Nov 2024205206124
Dec 2024385389255
Jan 2025546546378
Feb 2025418418295
Mar 2025473471377
Apr 2025410410303
May 2025408409293
Jun 2025238238158
Jul 2025110
Nov 2025220
Dec 2025200
Jan 2026210
Total952396484834